What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-speaking centers for allogeneic hematopoietic stem cell transplantation.
Survey of transplant practices documents current variation but offers limited new evidence to guide blood cancer patients toward optimal treatment pathways.
This survey study across German-speaking allo-SCT centers documents current practice variation in transplant pathways for MDS and AML. The practice variation data is useful for trial design but provides limited evidence-grade guidance on its own.
What the study was
- Study design
- Cross-sectional survey of transplant centers
- Population
- Hematologists at German-speaking allo-SCT centers; MDS/AML patients as indirect subjects
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Annals of hematology
Why it surfaced
Survey of transplant center practice for MDS/AML is informative for understanding the field but does not contribute new evidence. Useful for pipeline context on allo-SCT decision-making landscape in hematology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.